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Abstract 
Endothelial dysfunction in peritonitis: The formed concept of lipid distress syndrome 
(LDS) allows us to develop a working hypothesis on the key role of endothelial dysfunction 
in the aggressive development of atherosclerosis.   
The role of vascular endothelium in atherosclerosis: The process of NO production from 
L-arginine through eNOS involving tetrahydrobiopterin (BH4) is discussed.  With the 
degradation of BH4 along the free radical path, an "eNOS uncouplation" (uncoupled 
eNOS). 
The clinical role of statins: Statins manifests itself by inhibiting the enzyme 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG-CoA reductase). Many large, randomized clinical 
trials have shown that lipid-lowering strategies that include statins have an anti-atherogenic 
potential. 
Pleiotropic effects of statins: Direct inhibition of small GTP-ase prenylation in vascular 
cells forms the essence of the hypothesis that explains the rapid pleiotropic effect of statins 
on the vascular wall, which does not depend on reducing lipid levels. 
Endogenous antioxidant defense systems: Effects of stasms.  Statins have a beneficial 
effect on the vasculature not only by suppressing the prooxidant enzyme, but also by 
increasing the intensity and activity of endogenous antioxidant systems. 
The effect of statins on redox-sensitive transcritic pathways: One of the most important 
pathways is the NF-kB via the PI3K/Akt pathway.  
Experimental evidence of endothelioprotective properties of statins in the modeling 
of endotoxin-induced pathology: The use of HMG-CoA reductase inhibitors in the 
background of the fashion modeling endotoxin-induced pathology, leads to the 
development of a dose-dependent endothelioprotective effect, which is expressed in the 
normalization of QED, as well as the normalization of biochemical markers of 
inflammation (C-reactive protein) and the level of pro-inflammatory drugs. At the same 
time, positive dynamics of the final products of NO and eNOS expression was detected.  
Keywords: Statins, endothelial dysfunction, endotoxin-induced pathology, NF-kB and 
PI3K/Akt pathways. 
 
Endothelial dysfunction in peritonitis 
In recent years, works of VS Savlyev, VA 
Petukhov and co-authors put forward the concept 
of lipid distress syndrome (LDS) [1, 2, 3]. The 
concept was based on epidemiological studies, 
which indicate that in a remote period after an 
abdominal catastrophe in 10-20 years, patients 
develop atherosclerosis with catastrophic 
 
Rus.  
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consequences leading to the cardiovascular 
continuum [4].  The cause of arterial damage in 
persons who have undergone an abdominal 
catastrophe is not only endotoxin aggression, but 
also as a consequence of endothelial dysfunction 
with the further development of atherosclerosis 
and its complications [4, 5, 6, 7,]. 
In the opinion of the authors, endotoxin 
aggression accompanies the human body from 
early childhood, but clinically significant 
pathology develops only when endotoxin-binding 
and endotoxin-limiting organism systems are 
damaged [8].  In case of abdominal catastrophe, 
excess amounts of endotoxins enter the 
bloodstream to disrupt the adaptive capacity of 
these systems and multi-organ failure [9] It can be 
assumed that infectious diseases without adequate 
antibiotic therapy similarly deplete the 
antiendotoxin defense mechanisms, which 
primarily include high-density lipoproteins and 
lead to development  endothelial dysfunction of 
atherosclerosis [10] It seems that endotoxemia is 
a starting point in the development of  
lorganorganic disorders with LDS.  Further long-
term endotoxinemia against the background of the 
dysbiosis of the gastrointestinal tract forms the 
conditions for the progression of endothelial 
dysfunction [11]. 
Researches of the last years confirmed a role 
of endothelial dysfunction in a pathogenesis of 
many cardiovascular diseases. Clinical 
implication of endothelial dysfunction is the 
perversion of reaction to influence of 
physiological or pharmacological incentives 
when normal vessels react dilatation. Gravity of 
atherosclerotic process always correlates with 
endothelial dysfunction, and standard therapy of 
cardiovascular diseases doesn't eliminate 
endothelial dysfunction, and keeps risk of 
development of complication in several times [3, 
6, 11]. 
It is possible to believe, that the trigger of 
endothelial dysfunction is the Gram – 
липополисахарид. At the same time realization 
has the prescription mechanism at the low 
concentrations, and at high – macrophagic CD 14 
the effect is complemented with other 
mechanisms enlarging permeability of an 
endothelium [5, 12]. 
Developing in the abdominal catastrophe, 
endothelial dysfunction can not be treated in 
isolation as soon as arteriolar vasculitis, an 
important role in the sequence of events plays the 
liver as the main target organ of LDS.  Stimulated 
Kupfer cells reduce the synthesis of NO by 80-
90%, causing local dysfunction of the hepatic 
vessels, followed by a powerful release of pro-
inflammatory cytokines into the inflammatory 
bloodstream [13, 14].  At the same time, the 
concentration of TNF, C-reactive protein and 
other cytokines [15] and oxidized low-density 
lipoproteins significantly increase. The latter 
leads to a decrease in the synthesis of heparan and 
an increase in the size of the interendothelial gaps 
[16, 17, 18].  It is important to note that even a 
short-term increase in vascular permeability for 
macrophages with further endotoxin exposure 
significantly enhances endothelial dysfunction.  
At the same time, the protective role of high-
density lipoproteins in limiting the activity of 
macrophages weakens [11, 19, 20].  At the same 
time, in addition to para- endothelial transport, the 
mechanism of transfer is accelerated by the co-
endothelial mechanism and its activity is 
proportional to the level of endotoxemia [21]. 
The levels of P-selectin, interleukin 6 and 
others are the main markers of endothelial 
dysfunction [22, 23].  In clinical practice, a c-
reactive protein is often used [24]. The 
quantitative determination of the latter correlates 
with Interleukin 1, Interleukin 6, TNF [25, 26]. 
C-reactive protein in its turn participates in 
the migration of monocytes to the atherosclerotic 
plaque and stimulates the formation of "foamy" 
cells by enhancing the capture of low-density 
lipoproteins by macrophages. 
According to Savelyev V.S., Petukhov V. A., 
the information value S-reaktivnog about protein 
can SRB&gt; the relation of "XC/LPNP"&gt; 
LDL&gt; XC&gt; гомоцистеин&gt; LP [9] is 
presented in the following form. 
In this regard authors allocate several stages 
an endotoxin – the induced endothelial 
dysfunction. 1 stage – damage of a glycocalyx of 
an endothelium, 2 stage  – permeability 
augmentation, 3 stage -damage, the last is fixed 
by emergence in a blood flow of the 
endotheliocytes circulating in a blood flow [12, 
14, 18, 27, 28] 
At early stages of atherosclerotic process, the 
formation of atherosclerotic and vasculitis is 
preceded by a thickening of the vascular wall.  
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This quantitative indicator received the name 
intimamedia thicknes a complex of the "erotic 
media" of KIM [2, 7, 29] Essential value in recent 
years had an opportunity of an intravital not 
invasive research by means of an US, a dopler and 
td.  UZVR technique (ultrasound of high 
resolution) the offered D.S.  Celermajer et al.  on 
the humeral artery, the greatest distribution [7, 8] 
Pharmacological correction of LDS syndrome 
in abdominal catastrophe according to Saveliev VS  
and Petukhov VA  [9] should be reduced to two 
components: 1 – endotoxin binding therapy 
(enterosorbent, plant hepatoprotectors, probiotics 
of metabolic action 2 – endothelioprotection 
(quircetin-glucoronide of red leaves of grapes) 
 Based on the above, one can conclude that 
the formed concept of LDS syndrome as  the 
consequence of abdominal catastrophe allows us 
to develop a working hypothesis on the key role 
of endothelial dysfunction in the aggressive 
development of atherosclerosis and its 
complications that lead to the cardiovascular 
continuum.  This hypothesis is confirmed by 
numerous data on the dynamics of biochemical 
markers of endothelial dysfunction (C-reactive 
protein, pro-inflammatory cytokines, circulating 
endotheliocytes), as well as the results of 
instrumental studies of ultrasonic tomography 
with evaluation of the intima-media complex and 
endothelium-dependent vasodilatation.  
At the same time, the following questions 
arise: 
Any endotoxemia can induce endothelial 
dysfunction or  caused exclusively by 
lipopolysaccharides of  Gram  negative bacteria 
as for peritonitis ?;   
What experimental models besides peritonitis 
can be used for the development of endotoxin-
induced endothelial dysfunction ?; 
Which of the biochemical markers of 
endothelial dysfunction or their combination with 
functional studies most adequately quantify the 
development of endotoxin-induced endothelial 
dysfunction ?;  
Separate discussion requires a strategy of 
pharmacological correction of endotoxin-
inducing endothelial dysfunction and the 
prevention of aggressive development of 
atherosclerosis. We basically agree with the first 
part of endotoxin-binding therapy, especially in 
conditions of peritonitis and other conditions, 
accompanied by an infectious-toxic shock.  
However, the use of the term vegetable 
antioxidants as endothelial protectors from the 
standpoint of modern pharmacology is not 
sufficient.  In this connection, in the following 
sections of the review, we propose to discuss the 
possibility of the pathogenetically justified use of 
HMG Co-A reductase inhibitors both in 
monotherapy and in combination with the donor 
NO L-arginine, nonselective and selective 
inhibitors of arginase and recombinant 
erythropoietin. 
The role of vascular endothelium in 
atherosclerosis 
As it known, endothelial dysfunction is 
currently considered as one of the key triggers in 
the development of the atherosclerotic process. 
Endothelial dysfunction is characterized by 
reduced availability of NO. This causes an 
increase in intracellular cyclic GMP, and induces 
vasodilation.  In addition, NO also participates in 
the regulation of other processes, such as platelet 
aggregation and leukocyte adhesion, and plays an 
important role in vascular homeostasis [29].  The 
main enzymatic source of NO in the vascular wall 
is the endothelial synthetase of nitric oxide 
(eNOS), which is located mainly in endothelial 
cells.  eNOS is a complex that uses L-arginine and 
molecular oxygen (O2) as a substrate for the 
production of NO and L-citrulline. 
This is achieved by electron transfer using 
NADPH as a donor from the flavin reductase 
domain from one monodomain to the other where 
the active gemm-iron site [30, 31] is located. The 
presence of calmodulin, which activates calcium 
binding, increases the rate of electron flow.  In 
place of the heme, electrons are used to reduce 
and activate O2, which in turn is used to produce 
NO through the two-step oxidation of L-arginine.  
This process requires the binding of the cofactor 
tetrahydrobiopterin (BH 4). The enzyme that 
limits the rate of biosynthesis of BH 4 is called 
cycloshydrolase guanosine triphosphate 
(GTPCH).  When BH 4 is associated with eNOS, 
the enzyme is considered "linked" [3].  The 
adhesion of eNOS is important for the 
physiological function of the vascular 
endothelium.  Degradation of BH 4 on the free 
radical path, especially with peroxynitrite 
(ONOO -), leads to a condition known as 
"uncoupling eNOS" of the enzyme.  In the 
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absence of BH 4, the electron flux in eNOS is 
disrupted;  this leads to the dissociation of a 
divalent-molecular oxygen complex, resulting in 
eNOS for converting O2 to superoxide (O2 -) 
radicals instead of producing NO [32].  O 2 – 
reacts with NO to form ONOO -, which can 
additionally oxidize to BH 4, creating a vicious 
circle of eNOS disconnection.  As a result, the 
drop in NO production inhibits endothelium-
dependent vasodilation, disrupts vascular 
homeostasis and leads to endothelial dysfunction 
[31].  In addition, ONOO – has a fixed role in the 
oxidation of low density lipoprotein (LDL), and is 
also responsible for the nitration of various 
cellular components.  The accumulation of 
nitrated proteins is a potent marker of oxidative 
nitroergic cell damage. ONOO – and can induce 
cell apoptosis and necrosis even at high 
concentrations, further exacerbating endothelial 
dysfunction [33]. 
Endothelial dysfunction was established as 
an important predictor of future cardiovascular 
events, regardless of other risk factors.  A number 
of studies have shown a link between impaired 
endothelium-dependent vasodilatation of the 
brachial artery and an increased risk of 
cardiovascular complications in patients 
undergoing vascular surgery [34], including in the 
absence of obstructive arteriosclerosis [35].  
Recently, using meta-analysis, it was concluded 
that an increase in the diameter of the brachial 
artery during the cuff test is inversely associated 
with the risk of the cardiovascular continuum.  At 
the same time, the risk is more pronounced in 
populations at high risk in the presence of 
traditional predisposing factors, and an increase in 
vasodilatation of the brachial artery by 1% leads 
to a 9% decrease in cardiovascular risk [36].  
Oxidative stress and atherosclerosis. 
Modern understanding of the pathogenesis of 
cardiovascular diseases confirms the important 
role of free radicals (ROS) in atherogenesis [37].  
Classical risk factors for atherosclerosis, such as 
diabetes mellitus, hypertension and smoking, are 
associated with increased production of ROS in 
the vascular wall [38].  One of the main factors in 
the development of the atherosclerotic process is 
the oxidation of lipoprotein molecules.  First of 
all, the reaction of LDL + ROS leads to the 
formation of oxidized low density lipoproteins 
(oxLDL).  This occurs primarily in the 
subendothelial space, rather than in the plasma, in 
which there are many antioxidant defense 
mechanisms [39, 40].  ROS-mediated dissociation 
of eNOS causes dysfunction of the endothelium 
layer, through the mechanisms presented earlier.  
The binding of oxLDL to a lectin-like receptor 
induces activation of redox, proinflammatory 
transcription pathways (eg, nuclear factor kappa 
B [NF-kB]) in endothelial cells.  This induces the 
release of inflammatory cytokines (such as 
interleukin-6 (IL-6) and increases the expression 
of cell adhesion molecules (eg, vascular adhesion 
molecule 1 (VCAM-1).)   As a result, circulating 
monocytes are attracted to the vascular 
endothelium, where they adhere to the increased 
expression of adhesion molecules and penetrate 
the subendothelial space.  There they absorb 
(phagocytrate) oxLDL molecules, acquire 
microphage-like characteristics, and eventually 
turn into foamy cells.  This further exacerbates the 
inflammatory processes triggered in the vascular 
wall and creates a vicious circle where more 
monocytes / macrophages are attracted to the 
subendothelial space.  In addition, ROS 
inflammatory cytokines cause the migration of 
smooth muscle vascular cells in the intima.  The 
accumulation of saturated lipid membranes of 
foam cells and the parallel migration / spread of 
smooth muscle cells ultimately lead to the 
formation of atherosclerotic plaques.  
Despite the obvious role of oxidative stress in 
the development of atherosclerosis, the actual 
causal relationship in the human body has not 
been conclusively proven.  There is a question: – 
is the accumulation of ROS the cause of 
atherosclerosis or free radicals appear during its 
development [40].  Prove a causal relationship is 
difficult.  Oxidative stress is widely studied in 
experimental models.  Clinical studies have 
yielded results that are largely consistent with 
fundamental research.  Thus, oxidative stress is 
now universally recognized as one of the key 
components of cardiovascular disease [39, 40].   
Taking into account the participation of ROS 
in the pathogenesis of atherosclerosis, a 
therapeutic approach is designed logically to 
introduce biologically active antioxidant 
supplements such as ascorbic acid (vitamin C), 
alpha-tocopherol (vitamin E), and others.  These 
compounds act as exogenous traps of free radicals 
and their use was considered a rational therapeutic 
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strategy for restoring the vascular oxidation-
reduction balance and preventing cardiovascular 
diseases.  Indeed, since 1994, more than 50 large 
randomized studies that used antioxidant vitamins 
in primary and secondary prevention of 
cardiovascular disease have been published, with 
disappointing results.  The latest meta-analysis, 
based on the total population of nearly 300,000 
participants, scattered across 50 randomized 
trials, concludes that there is no evidence to 
support the use of antioxidants for the prevention 
of cardiovascular disease [41].  
The disappointing results of the use of 
antioxidant additives, in our opinion, should in no 
case be interpreted as invalidating the hypothesis 
of oxidative stress.  For example, Patrignani et al. 
[42, 43, 44, 45] found that supplements with doses 
of vitamin E to 1200 mg / day did not affect the 
urinary concentration of 8-iso-PGF2a (a 
noninvasive marker of oxidative stress in vivo) in 
healthy  smokers.  In contrast, comparable doses 
of vitamin E significantly affect the level of 8-iso-
PGF2a in clinical settings in patients with risk 
factors for cardiovascular disease.  It is interesting 
that there is a linear correlation between the basal 
rate of excretion of 8-iso-PGF2a and changes in 
this index of lipid peroxidation depending on 
changes in the level of vitamin E in plasma. These 
results are consistent with the hypothesis that the 
basal rate of lipid peroxidation is the main factor 
determining  response to the exogenous 
introduction of vitamin E. 
The clinical role of statins: an effective 
lipid-lowering strategy  
Statins are organic molecules, originally 
derived from fungi.  They exhibit their effect by 
inhibiting the enzyme 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA 
reductase) by competitive inhibition of substrate 
binding to the active site of the enzyme, due to 
their structural similarity to HMG-CoA [46, 47]. 
Inhibitors of HMG-CoA reductase is a rate-
limiting enzyme in the biosynthesis of 
cholesterol.  This enzyme converts HMG-CoA to 
mevalonate, which is then phosphorylated and 
converted to isopentenyl pyrophosphate (IPP) and 
dimethylallyl pyrophosphate (DMAPP).  These 
molecules serve as isoprenoid precursors farnesyl 
pyrophosphate (FPP), which is converted to 
geranyl-geranium pyrophosphate (GGPP) and 
squalene.  In hepatic cells, squalene forms the 
basis of ergosterol and subsequently the synthesis 
of cholesterol.  Since a significant percentage of 
total cholesterol in the human body is 
endogenously produced, inhibition of HMG-CoA 
by statins leads to a subsequent decrease in 
cholesterol and, in particular, low-density 
lipoprotein [48].  
Many large randomized clinical trials have 
shown that lipid-lowering strategies that include 
statins have an anti-atherogenic potential and 
reduce the risk of developing myocardial 
infarction and stroke. A 31% decrease in the 
number of coronary events in 
hypercholesterolemic patients after treatment 
with pravastatin (40 mg / day) [49, 50].  A recent 
review of the Cochrane database leads to the 
conclusion that statins reduce vascular 
complications and mortality from all causes in 
patients with no history of coronary artery disease 
[50].  Similarly, prolonged use of pravastatin in 
patients with ischemic disease demonstrates a 
significant reduction in coronary death from all 
causes in patients receiving pravastatin (40 mg / 
day [51]. In addition, in patients with CABG, 
aggressive lovelopidemic therapy of lovastatin + 
cholestyramine was more effective in  compared 
with more conservative treatment [52]. As a result 
of these and other large-scale studies, statins are 
integral part of the drug therapy that 
recommended after major cardiovascular event.  
The latest WHO recommendations and the 
Russian guidelines recommend the initiation of 
statin therapy as a secondary prophylaxis in the 
presence of ischemic heart disease or other 
atherosclerotic vascular disease (class IA), with 
target LDL levels below 100 mg / dl, directed at 
least by reduction  30% of previous levels [53]. 
The pleiotropic effects of statins  
Most of the early clinical trials of statins have 
been focused on correcting dyslipidemia in 
patients with CVD with high LDL cholesterol.  
However, an analysis of further studies reveals the 
beneficial effect of statin therapy in patients with 
CVD on newly diagnosed coronary heart disease 
or in patients who need revascularization, 
regardless of their LDL level [54, 55, 56, 57].  
Similarly, post-factum analysis of the POST-
CABG study shows a positive effect of intensive 
statin therapy on cardiovascular disease 
regardless of the decrease in lipid levels [55, 56, 
57].  The concept, that statins can potentially have 
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effects beyond hypolipidemic capabilities is 
further enhanced by the verdict of the JUPITER 
trial in which non-lipidemic healthy subjects with 
high C-reactive protein levels (CRP) were 
randomized to receive rosuvastatin 20 mg / day or 
placebo [58] .  The results of this study show that 
treatment with statins reduces the level of CRP 
and the frequency of major cardiovascular events.  
The effects of statins do not depend on LDL.  This 
decrease in the level of C-reactive protein was 
termed "pleiotropic" and was the focus of 
extensive research in the last decade.  
Direct pleiotropic effects of statins on 
vascular endothelial function in humans have 
been demonstrated by comparing the effects of 
various lipid-lowering strategies.  In a 
randomized trial of patients with chronic heart 
failure for 4 weeks with simvastatin or ezetimibe 
(10 mg / day), statin showed a marked 
improvement in the results of the cuff test on the 
brachial artery compared with ezetimibe, despite 
a similar reduction in LDL levels  [59, 60].  
Similarly, in patients with dyslipidemia without 
cardiovascular disease, 40 mg / day of simvastatin 
improved cuff test results and the level of vascular 
Rho kinase was significantly higher than 
simvastatin 10 mg / day plus ezetimibe 10 mg / 
day [61].  Another recent meta-analysis, which 
examined the effects of statin therapy on cuff test 
results in diabetic patients, concluded that statins 
improve endothelial function, but only in patients 
who have no signs of severe endothelial 
dysfunction [62].  The latter highlights the role of 
prevention and modification of risk factors that 
can be realized with the use of statin therapy.  
Interesting, theat sudden cessation of treatment 
with simvastatin in patients with coronary heart 
disease leads to a significant reduction in the 
cuffing in the cuff sample in the first week after 
cessation of treatment, the effect does not 
correlate with an increase in rebound levels of 
LDL [63].  Conversely, in healthy people, the 
abrupt discontinuation of statin treatment also 
leads to a reduction in vasodilation in the cuff test 
on day 1 after discontinuation, which is restored 
to baseline within 1 week [63].  These results 
emphasize the potential of endothelium-
protective pleiotropic effects of statins, as well as 
the need for an appropriate treatment regimen.  
As mentioned earlier, isoprenoids FPP and 
GGPP are intermediate products of cholesterol 
biosynthesis, which is inhibited by statins.  
Protein prenylation is an important post-
translational modification.  The family of small 
GTP-as (Ras, Rho, Rac, etc.) is an important 
cellular target for prenylation.  The addition of 
FPP or GGPP residues in proteins is crucial for 
lipid anchoring and activation of Rho and Rac 
[64]. Geraluleranization from Rho activates Rho-
associated protein kinase (ROCK);  Po / ROCK 
pathway is involved in the control of various 
cellular functions, including proliferation, cell 
migration, oxidation-reduction signaling and 
apoptosis [65, 66].  In addition, Rac is involved in 
the activation of the NADPH oxidase complex 
and thus plays an important role in regulating the 
generation of reactive oxygen species, as will be 
discussed in detail later.  
 Cholesterol biosynthesis is active not only in 
hepatocytes, where it was first described, but it is 
also important for the cellular homeostasis of 
vascular cells.  Lipophilic statins (for example, 
atorvastatin and simvastatin) can passively 
diffuse through the lipid bilayer of the cell 
membrane and, therefore, can be assimilated by a 
large number of cells, and not only by hepatocytes 
(which also have such active transport 
mechanisms) [67].  Direct inhibition of small 
GTP-ase prenylation in vascular cells forms the 
essence of the hypothesis that explains the rapid 
pleiotropic effect of statins on the vascular wall, 
which does not depend on lowering lipid levels 
[67, 68]. 
Sources of free radicals as therapeutic 
targets of statins in the vascular wall. Cell redox 
imbalance, characterized by increased production 
and reduced utilization of ROS, is involved in 
many pathophysiological processes, including the 
development of cardiovascular diseases.  Statins 
are probably the most effective and currently 
available pathway that inhibits prooxidant 
enzyme systems present in the vascular system 
and enhances antioxidant defense mechanisms.  
The effect of statins on the redox systems of the 
cell has been extensively studied in cell cultures 
in vitro.  Nevertheless, the results obtained in 
experiments performed in such "model systems" 
do not necessarily reflect the processes in vivo 
and can not be applied to human diseases.  A large 
number of experiments have been performed in 
human umbilical vein endothelial cells, which 
have significant functional differences compared 
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to arterial endothelial cells, which are directly 
related to the development of atherosclerosis. 
The effect of statins on eNOS. The effect of 
statins on eNOS is well documented in the 
literature.  It has been proven that pleiotropic 
effects of statins in the vasculature are at least 
partially mediated by changes in eNOS 
expression.  
It was shown that geranylgearylation from 
GTPase Rho leads to a decrease in eNOS in the 
endothelial cell.  Statin therapy is inhibited by 
GGPP formation and therefore leads to increased 
expression of eNOS, which was revised in the 
case of co-incubation with GGPP [69, 70].  
Increased endogenous levels of LDLs also 
adversely affect the expression of mRNA in 
eNOS [71].  The mechanism by which statins 
increase the stability of eNOS mRNA is an 
increase in the eNOS mRNA of polyadenylation, 
due to changes in the cytoskeleton, after Rho 
inhibition [71].  In addition, the exposure of the 
H2O2 -induced, aging, smooth muscle cells to 
statins activates the phosphatidylinositide of the 
3-kinase (PI3K) / Akt pathway and enhances the 
expression of eNOS [72].  More recently, eNOS 
mRNA has been identified as a target of micro-
RNA-MIR-155, which is activated by 
inflammatory stimuli, such as tumor necrosis 
factor alpha (TNF).  It is important to note, that 
this effect was weakened by simvastatin.  The 
beneficial effect of statin was found when 
combined with megalonate or GGPP.  
Interestingly, the authors mimicked the effect by 
inhibiting RhoA, suggesting that the mevalonate / 
GGPP / RhoA pathway underlies the observed 
effects of simvastatin at the microRNA-155 level 
[73].  In animal experiments with diets induced by 
endothelial dysfunction, increased expression of 
eNOS mediated by statins leads to an 
improvement in endothelial function [74]. 
In addition to increasing the expression of 
eNOS at the transcriptional and post-
transcriptional levels, statins cause an increase in 
eNOS activity at the post-translational level.  
eNOS has several sites of phosphorylation 
activation.  The effect of fluvastatin on smooth-
muscle cells of the human umbilical cord showed 
an increase in the phosphorylation of eNOS upon 
activation of Ser-633 and Ser-1177 genes via 
protein kinase A (PKA) – and PI3K / Akt-
mediated pathway, respectively [75].  The statin-
induced induction of eNOS phosphorylation by 
Ser-1177 is realized through the heat shock 
protein-90 [76].  On endothelial cell culture, it 
was shown that atorvastatin to increase eNOS 
phosphorylation by Ser-633 in adenosine 
monophosphate-activated protein kinase (AMPA) 
-mediated pathway [77].  In addition, in 
experiments on the mesenteric artery of rats 
incubated with simvastatin, it was found that the 
drug causes rapid AMPK-mediated 
phosphorylation of eNOS on Ser-1177 [78].  This 
leads to an improvement in endothelium-
dependent vasodilation.  The effect is removed 
both by inhibiting eNOS L-NAME and by joint 
incubation with mevalonate. In addition, statins 
also increase eNOS activity at the post-
translational level by inducing its dissociation 
from caveolin-1.  Caveolae are invaginations of 
the cytoplasmic membrane, formed mainly by the 
protein caveolin-1, which has the ability to bind 
eNOS and inhibit its enzymatic activity.  
Atorvastatin reduces the content of caveolin-1 
and activates eNOS in endothelial cells, 
regardless of the presence or absence of LDL 
cholesterol [76].  This mechanism was also 
demonstrated in experiments on apolipoprotein E 
deficient mice, where rosuvastatin reduced 
caveolin-1 and improved cardiac function and 
blood pressure variability [79, 80]. 
Activation of eNOS does not necessarily 
result in an improvement in NO production.  If 
there is significant dissociation of eNOS, then its 
phosphorylation causes induced activation to 
increase production of O 2 – instead of NO [81].  
Nevertheless, cerivastatin or fluvastatin to 
prevent the dissociation of eNOS increase the 
expression and bioavailability of BH 4 in human 
umbilical cord endothelial cell culture [75, 82, 
83].  In the experimental model of diabetes in 
laboratory animals, the administration of 
atorvastatin prevents the separation of NOS 
through the same mechanism [84].  Recently, in a 
randomized, double-blind, placebo-controlled 
clinical trial, it was demonstrated that on the 3rd 
day of treatment with atorvastatin (40 mg / d) in 
patients after coronary artery bypass grafting, the 
level of BH 4 and eNOS of the internal thoracic 
artery increased compared to the placebo group 
[85].  This is accompanied by an improvement in 
the results of the cuff test on the brachial artery.  
It is important that these effects are rapid and 
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independent of the lipid-lowering effect of 
atorvastatin.  In experiments on isolated segments 
of the human thoracic artery, atorvastatin causes 
an increase in the expression of the GCH1 gene, 
encoding guanidine triphosphate cyclohydrolase 
followed by an increase in the level of total 
tetrahydrobiopterin.  The effect was reversed by 
joint incubation with mevalonate [85]. 
There is another mediated mechanism by 
which statins can enhance eNOS activity, 
improve its communication and enhance 
metabolism or prevent ADMA effects.  
Endothelial cells exposed to ADMA exhibit an 
increased inflammatory response, which is 
markedly reduced by the action of simvastatin 
indirectly through the extracellular pathway of the 
kinase receptor [86].  Treatment of rats with 
spontaneous hypertension with rosuvastatin 
revealed a decrease in the level of circulating 
ADMA and a decrease in vascular oxidative 
stress, regardless of the decrease in cholesterol 
[87].  Similarly, in the rat model of pulmonary 
hypertension, rosuvastatin increases DDAH 
expression, and then decreases serum ADMA 
levels, while increasing eNOS phosphorylation 
through the PI3K / Akt pathway [88].  
Nevertheless, the results of clinical studies were 
contradictory.  Some randomized studies have 
shown that short-term statin therapy reduces the 
level of circulating ADMA in humans [89, 90, 
91], while other studies have not been able to find 
such an effect [92, 93, 94].  These conflicting 
results might be related to differences in the 
characteristics of the patients examined.  It is 
interesting to note that in a small randomized trial, 
simvastatin failed to improve endothelial function 
in patients with high ADMA levels, but managed 
to do this in combination with oral administration 
of L-arginine in patients with low ADMA [95]. 
The effect of statins on NADPH oxidases.  
NADPH oxidase is the most important source of 
ROS in the vasculature, both in isolated segments 
of the arteries, and in culture of human umbilical 
vein endotheliocytes.  It catalyzes the conversion 
of O 2 into O 2 • – radicals, using NADPH as an 
electron donor.  This membrane-bound enzyme 
complex;  components that depend on the 
corresponding homologue of the membrane 
subunits: Nox1-5 and Duox1 or 2. Endothelial 
cells possess Nox2, nox4 and Nox5, while Nox1, 
nox4, and Nox5 were found in the umbilical cord 
endotheliocytes.  Nox2 is a form of the enzyme 
present in phagocytes.  It consists of two 
membrane-associated subunits, p22 phox and 
gp91 phox-Nox2 (which make up the complex 
with cytochrome b558), as well as four cytosolic 
subunits, p40 phox, p47 phox, p67 phox and 
RAC1 or 2, which upon stimulation are 
transformed with flavocytochrome  b558, which 
can lead to the assembly and activation of the 
enzyme complex.  The activity of Nox1 and Nox2 
can be stimulated with angiotensin II, growth 
hormone and pro-inflammatory cytokines, via 
p47phox phosphorylation [96].  At the same time, 
Nox5 is in a state without a Ca-dependent 
stimulation [97].  Conversely, nox4 does not 
require ROS for activation [96]. It has been found 
that increased expression and activity of NADPH 
oxidase isoforms in the vasculature, together with 
increased production of ROS, contribute to the 
onset and maintenance of the atherosclerotic 
process.  Nevertheless, it should be noted that 
recent studies have found a potentially useful role 
for the ROS-independent nox4 isoform in the 
vascular wall, by increasing vasodilation in the H 
2 O 2 -mediated pathway [98]. 
A significant number of publications are 
devoted to the role of statins in inhibiting the 
activity of NADPH oxidase.  As mentioned 
earlier, activation of ROS and its localization in 
the membrane is necessary for the activation of 
Nox1 and 2-complexes, which are widely 
distributed in vascular cells and are involved in 
the pathophysiology of atherosclerosis.  The most 
important step in the activation of ROS is its 
geranylgernaliticim on geranyl-geranyl 
triphosphate through biosynthesis of cholesterol.  
Given that statins suppress both the formation of 
isoprenoids and geranyl-geranyl triphosphate, a 
large number of studies have attempted to 
determine whether inhibition of HMG-CoA 
reductase can lead to a decrease in the activity of 
NADPH oxidase. 
In experiments on culture of human umbilical 
cord endotheliocytes, statin therapy reduced p22 
phox mRNA and p47 phox protein levels [99].  
Endotheliocytes of human umbilical arteries 
under the influence of atorvastatin reduce the 
expression of Nox1 in the membrane localization 
of Rac1, which leads to a decrease in the 
production of ROS [100].  Statins can also inhibit 
the generation of reactive oxygen species in 
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isolated segments of coronary arteries of pigs, 
reducing p22 phox levels of mRNA [101]. Thus, 
cerivastatin in human cord tissue culture of 
endotheliocytes induces the activation of LPO in 
the Rac1 region, followed by activation of 
NADPH oxidase and an increase  O2 – [102]. The 
mechanism by which NADPH oxidase exerts its 
effect is the colocalization of the acid ceramic of 
sphingomyelinase with the formation of 
membrane adhesions in the cell membrane.  Statin 
treatment prevents the formation of these 
membrane adhesions induced by low-density, 
oxidized lipids, and then reduces the generation of 
O 2 – [103]. 
The effects of statins on NADPH oxidase 
have also been studied in animal models 
simulating cardiovascular pathology.  Thus, the 
administration of statins in rats suppressed the 
activity of NADPH oxidase by means of 
mevalonate-dependent activation of ROS.  This 
resulted in improved vascular NO production and 
further improvement in endothelial function 
[104].  In experiments with the modeling of 
atherosclerosis in rabbits, fluvastatin prevented an 
increase in p22 phox and gp91 phox induced by a 
high fat content and improved endothelial 
function and reduced plaque size [105].  
Similarly, simvastatin suppressed generation of 
reactive oxygen species and restored endothelial 
function in rats with modeling of diabetes mellitus 
[106].  In the normocholesterolemic model of 
hypertension in rats, statins reduced the 
expression of the p22 phox and Nox1 [100] gene, 
as well as the levels of the p22 phox protein of the 
angiotensin I receptors, and there by reduced the 
production of oxygen reactants and improved 
endothelial function [107].  In the experimental 
model of ischemic stroke in rats, atorvastatin 
prevented an increase in generation and NADPH 
oxidase activity of the ROS in, by reducing the 
gp91 phox levels of mRNA and P47 phox 
localized in the membrane [108].  On the other 
hand, statins prevent the development of 
endothelial dysfunction in mice through Rac1-
mediated activation of NADPH oxidase [109]. 
The cultivation of the cell lines obtained from 
patients demonstrated the relevance of the above 
observations to human physiology.  Thus, 
treatment with statins reduced the level of gp91 
phox in cultures of endotheliocytes of the internal 
thoracic arteries of a person obtained from 
patients undergoing aorto-coronary bypass 
grafting [110].  In a cross-over study, it was found 
that treatment with statins with hyperlipidemia 
leads to a decrease in the level of circulating gp91 
phox, as well as markers of systemic oxidative 
stress [111].  The blockade of AT1 receptors in a 
randomized group of 49 patients with cholesterol-
dependent oxidative stress after aorto-coronary 
bypass surgery compared with the placebo group 
showed that pravastatin (40 mg / day), irbesartan 
(150 mg / day), or both for 4-  x weeks showed a 
significant positive effect [112].  Thus, statin 
therapy as well as combination therapy 
significantly increased eNOS expression and 
suppressed gp91 phox in the brachial artery 
during the cuff test, which indicates a synergistic 
effect on endothelial function, regardless of LDL-
lowering effects [112].  Recently, it has been 
shown that short-term treatment with atorvastatin 
rapidly suppresses O2 – the formation and activity 
of NADPH oxidase in patients undergoing 
aortocoronary bypass irrespective of LDL-
lowering effects [113].  This is also accompanied 
by a decrease in the plasma levels of malonic 
dialdehyde as a marker of systemic oxidative 
stress.  In vitro incubation of human 
endotheliocytes with atorvastatin results in a 
decrease in p67 phox and ROS localization in the 
membrane.  In this case, the effects were removed 
in the presence of mevalonate [113]. A similar 
mechanism of NADPH oxidase was found in 
human myocardiocytes [114]. 
Effect of statins on endothelial cells. As is 
known, endothelial cells synthesize prostacyclin 
(PGI 2) with the help of the enzyme PGI 2 – 
synthase.  Its molecule, the precursor of 
prostaglandin H2, is itself synthesized from 
arachidonic acid by oxidation of fatty acids with 
cyclooxygenase.  PGI 2 is an important 
vasodilator and an antithrombotic molecule that 
balances the effects of thromboxane A 2.  
Recently, it has been found that vascular PGI 2 
can participate in the regulation of eNOS 
expression [115].  Di Francesco et al. [116]  
showed that inhibition of cyclooxygenase-2 
induced by shift of heme oxygenase 1, results in 
the cessation of the effect of tumor necrosis factor 
in human endothelial cells [116].  Given that 
fluvastatin causes an increase in the expression of 
PGI 2 synthase and increases PGI 2 in human 
endothelial cells [117], this pathway can also 
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participate in the realization of vasoprotective 
effects of statins.  
 A statin-induced change in the activity of 
pro-oxidant enzymes may also partially explain 
the useful antithrombotic effects of statins, as 
evidenced by the reduced release of thromboxane 
A2 from the isolated rat aorta in the 
cyclooxygenase-2-mediated pathway [118]. 
Thus, the yield of 8-isoprostane is elevated in rat-
resistant hypertensive rats.  This is eliminated by 
the appointment of atorvastatin and improves 
endothelial function and restores the redox 
potential of the vascular wall [119].  Similarly, 
atorvastatin-induced modification of 5-
lipoxygenase leads to a reduction in the 
vulnerability of plaques in rabbits [120]. 
Endogenous antioxidant defense systems: 
effects of statins. Due to the constant impact of 
ROS, almost all living cells possess several 
enzyme antioxidant defense systems that control 
the final availability of ROS.  Superoxide 
dismutase (SOD) is an enzyme that catalyzes the 
conversion of O2 – to H2O 2.  Catalase is an 
enzyme located in peroxis that decomposes H2O 
2 in water and O2.  Glutathione (GSH) is a 
tripeptide that acts as an important antioxidant of 
the limiting effect of H2O2;  this is achieved by 
reducing the sulfhydryl groups in the cysteine 
residues of other proteins, thereby protecting 
these proteins from oxidative damage.  It is 
catalyzed by glutathione-S-transferase, as well as 
glutathione peroxidase (GSH-PXS), which leads 
to the formation of glutathione disulfide (GSSG) 
from two GSH molecules;  GSH can be 
replenished through the effects of glutathione 
reductase. The GSH / GSSG ratio is widely used 
as a cellular marker of oxidation-reduction 
processes.  Paraoxonase is an enzyme involved in 
protecting against oxidation of the LDL molecule.  
Other antioxidant enzyme systems are also 
present in cells such as thioredoxins, 
peroxedoxins, and so on. 
It has been shown that statins have a 
beneficial effect on the vasculature not only by 
suppressing the prooxidant enzyme, but also by 
increasing the intensity and activity of 
endogenous antioxidant systems, in experimental 
models and clinical studies. Symvastatin can 
partially restore the renal levels of all three major 
cellular antioxidant systems  protection (SOD, 
GSH-Px and catalase) and reduce levels of 
biomarkers of oxidative damage in diabetic 
animals [121, 122].  In addition, an improvement 
in endothelial function was found by increasing 
the SOD level in rats chronically treated with the 
eNOS L-NFME inhibitor [123].  The beneficial 
effect of atorvastatin on reducing the size of 
plaques in animals on an atherogenic diet was 
observed against the background of an elevated 
level of circulating paraoxonase [124].  
The effects of statins on catalase activity 
levels have been demonstrated in a number of 
studies.  For example, endotheliocytes of  aorta of 
rats and umbilical artery of a person show an 
increase in the levels of expression of genes and 
catalase proteins after treatment with atorvastatin 
[100].  The effect is mediated by PI3K / Akt by 
[125].  In addition, in animal models of 
hypertension and diabetes mellitus, statins 
increase the expression of aortic catalase [100, 
125].  An increase in statin-induced catalase 
levels has also been demonstrated with an 
aneurysm of the human abdominal aorta [126].   
The effect of statins on redox-sensitive 
transcritic pathways  
It has been established that the main 
mechanism by which ROS production contributes 
to the development of atherosclerosis is the 
initiation of oxidation-reduction sensitive 
transcriptional pathways in the vascular 
endothelium.  These pathways regulate the 
production of pro-inflammatory, pro-atherogenic 
cytokines and cellular components that enhance 
oxLDL and macrophage infiltration, as well as the 
proliferation and migration of smooth muscle 
cells to the intima.  One of the most important 
oxidation-reduction pathways is the NF-kB 
pathway.  NF-kB is a transcription factor that 
controls the expression of a large number of 
proinflammatory genes.  In its non-activated 
form, NF-kB is in the cytosol bound to its 
inhibitor (IκBα).  H2O2 was originally proposed 
as a candidate for direct activation of NF-kB 
[127].  Currently, it is understood that ROS have 
the ability to indirectly modulate the function of 
NF-kB [128].  Proinflammatory mediators, such 
as TNF;  activate IκB kinases (IKK).  This leads 
to its degradation, thereby freeing NF-kB 
molecules.  Therefore, NF-kB is translocated to 
the nucleus and binds to its response elements, 
initiating the transcription of pro-atherogenic 
mediators, such as IL-6, TNFα,  , adhesion 
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molecule VCAM-1 and intercellular adhesion 
molecule (ICAM) -1, and others.  Another pro-
inflammatory transcription factor that can be 
induced by ROS is a protein-1 activator (AP-1).  
Like NF-kB, AP-1 regulates the expression of 
genes involved in inflammatory processes, cell 
proliferation and apoptosis, and plays a role in the 
atherosclerotic process. 
The role of statins as potential inhibitors of 
NF-kB has been investigated in cell cultures 
where NF-kB activity was induced by various 
factors.  Atorvastatin prevented the induced TNFα 
and angiotensin II-induced activation of NF-kB 
and the subsequent release of inflammatory 
mediators.  Effects were prevented by farnesyl 
pyrophosphate (FPP) and geranyl-geranyl 
pyrophosphate (GGPP) [129].  Fluvastatin also 
attenuated CRP-induced activation of NF-κB in 
endothelial cells [130] of smooth muscle cells of 
the umbilical vessels [131].  Simvastatin and 
atorvastatin reduced oxLDL-induced activation 
of NF-κB in the human coronary artery [132].  
These statin-mediated effects have also been 
demonstrated in experimental models of 
cardiovascular disease.  Thus, simvastatin 
reduced NF-KB activity in atherosclerotic 
plaques and circulating mononuclears in animals 
with an atherosclerotic diet, regardless of 
hypolipidemic effects [133].  Similarly, the 
administration of cerivastatin significantly 
reduced the activity of NF-kB in the hearts 
induced by angiotensin II and did not affect the 
level of cholesterol in the blood [134].  LDL-
independent anti-inflammatory effects of statins 
have also been extensively studied in cellular 
models both at the forefront of atherosclerosis and 
inflammation induced by pathogenic 
microorganisms.  In the culture of human 
umbilical cord endothelial cells, the inflammation 
induced by Chlamydia pnevmonalae was 
significantly lowered under the influence of 
cerivastatin.  Similarly, the release of 
inflammatory mediators was reduced by 
suppressing the activation of NF-kB [135, 136]. 
Also, in the culture of portal vein endotheliocytes 
infected with cytomegalovirus, the effect of 
fluvastatin slowed the activation of NF-kB, which 
reduced viral replication [137].  
The impact of statins on the pathway of NF-
kB can play a decisive role in preventing 
monocyte infiltration, the formation of foam cells 
and the proliferation of smooth muscle cells of the 
vessels.  Simvastatin dose-dependently inhibits 
the TNF-induced increase in ICAM and VCAM-
1 in endotheliocyte culture of the portal vein due 
to decreased activation of NF-kB;  this leads to a 
decrease in the interaction of monocytes with 
endothelial cells [138].  Importantly, in vitro 
pravastatin prevents the effect of human 
monocytes on LDL-induced activation of NF-kB 
and the subsequent expression of inflammatory 
mediators [139].  In addition, atorvastatin inhibits 
interleukin-18 induced migration of smooth 
muscle aortic cells and the inactivation of NF-kB 
[140].  
Various hypotheses have been proposed to 
explain the ability of statins to reduce NF-kB 
activity.  It has been shown that statins cause an 
increase in the expression of IκBα genes in 
endothelial cells, and also reduce the expression 
of NF-kB and decrease binding to smooth muscle 
cell proteins, which leads to a general decrease in 
NF-kB activity in vascular cells [141].  In 
addition, statins decrease ROS-mediated 
activation of NF-kB in monocytes by decreasing 
the activity of IkB kinase [142].  
Phosphatidylisothiazidyl 3-kinase-independent 
pathway, which involves inhibition of the IkB 
kinase / Akt signaling pathway in human 
endotheliocytes [143].   
The ability of statins to inhibit NF-kB 
signaling has also been found in clinical studies.  
In a small nonrandomized study, the appointment 
of pravastatin (40 mg / day) 3 months before the 
planned carotid artery prosthetics led to 
stabilization of the plaque in the carotid artery, as 
evidenced by a decrease in NF-kB activation 
lipids [144].  In an aneurysm of the abdominal 
aorta simvastatin suppresses the generation of 
active oxygen species and the activity of NF-kB 
[145].  In a randomized trial, treatment with 
atorvastatin (80 mg / day) for 1 month prior to 
surgery resulted in a decrease in NF-kB activation 
in circulating mononuclears in combination with 
a decrease in inflammatory gene expression and 
cellular plaque infiltration [146].   
One of the main ways that is crucial for the 
cellular antioxidant response is the nuclear factor 
(erythroid origin 2 (Nrf2). In its non-activated 
form, Nrf2 is in the cytoplasm, binds to proteins 
callin 3 and endothelium-associated protein 1 
(Keap1).  cysteine residues that are sensitive to 
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changes in ROS because of their sulfhydryl group 
(-SH) .The oxidation of these -SH groups 
dissociates the callin3 / Keap1 complex from 
Nrf2, which translocates into the nucleus and 
initiates the transcription of genes encoding 
endogenous  antioxidant defense proteins It has 
been shown that simvastatin is able to activate 
Nrf2 via the PI3K / Akt pathway and then 
suppress the generation of reactive oxygen 
species in primary embryonic fibroblasts of the 
mouse [147] .A similarly, fluvastatin significantly 
increased the Nrf2 nuclear translocation in 
smooth muscle cells of the coronary artery 
through  the same intracellular pathway.This 
leads to increased activity of antioxidant enzymes 
and reduced production of ROS [148].  
Thus, the use of statins is currently a key 
strategy for reducing cardiovascular risk, both in 
primary and secondary prevention.  In addition to 
their hypolipidemic properties, statins also have a 
number of direct, or pleiotropic, effects on 
vascular function, suppressing atherogenesis, 
which in some cases may even lead to regression 
of atherosclerotic plaques. For the past decade, 
the vascular endothelium has been identified as 
one of the main targets  for antiatherogenic / 
pleiotropic effects of statins.  Statins have the 
ability to restore the physiological balance 
between NO and ROS in the vascular 
endothelium, through a series of LDL-dependent 
and -independent effects.  They increase 
expression, and the enzymatic activity of eNOS, 
the main source of O 2 • – radicals in the human 
vascular endothelium, which leads to an increase 
in NO biosynthesis. At the same time, they 
suppress the activity of prooxidant enzymes (such 
as NADPH oxidases, unbound Enos, and others) 
and increase the effectiveness of endogenous 
antioxidant systems in the vascular endothelium, 
which leads to a net reduction in ROS.  By 
restoring the balance between NO and ROS in the 
vascular endothelium, statins also control the 
activation of the inflammatory processes of the 
vessels, and prevent the proliferation / migration 
of smooth muscle cells and lead to suppression of 
atherogenesis. 
At the same time, there are several 
unresolved issues that need to be understood 
regarding the biological role of statins.  
1. Their indirect influence requires study.
For example, by changing the biology of 
perivascular fat tissue, which has a paracrine 
effect on the vascular wall.   
2. The role of statin therapy in the
pathogenesis of vascular disease and especially 
in atherosclerosis is clear.  Statins are now 
involved in all therapeutic strategies in primary 
and secondary prevention of the cardiovascular 
system.  They stabilize atherosclerotic plaques 
and improve survival (3).  However, it is difficult 
to imagine that these effects are mediated 
primarily because of their direct or indirect 
"antioxidant capacity."  Further studies are 
needed to study the efficacy of statins in other 
cardiovascular diseases with a large involvement 
of ROS in their pathogenesis.  The last in full 
priory refers to endotoxin-induced pathologies.  
This would further expand their broad clinical 
application.  
3. Finally, the ability of statins to exert a
biological effect on the vascular endothelium, 
regardless of their primary pharmacological 
action, can serve as a "pharmacological model" 
for the development of new antioxidant strategies 
that aim to control the intracellular balance 
between production / elimination.  These smart 
strategies should aim to imitate the pleiotropic 
effects of statins on the vascular endothelium. 
Experimental evidence of 
endothelioprotective properties of statins in 
the modeling of endotoxin-induced pathology 
The use of simvastatin HMG-CoA reductase 
inhibitors (2.2, 4.3 and 8.5 mg / kg), atorvastatin 
(1.1, 2.2 and 4,  3 mg / kg), rosuvastatin (2.2, 4.3 
and 8.5 mg / kg) and nanoparticulated 
rosuvastatin (3, 6.3 and 11.6 mg / kg) against the 
background of endotoxin-induced pathology 
modeling leads to  the development of a dose-
dependent endothelioprotective effect, expressed 
in the normalization of QED, the prevention of 
increased adrenoreactivity and exhaustion  
myocardial reserve, as well as the normalization 
of biochemical markers of inflammation (C-
reactive protein) and the level of pro-
inflammatory cytokines.  At the same time, 
positive dynamics of the final products of NO and 
eNOS expression was detected.  It is noteworthy 
that the most effective was the nanoparticulated 
form of rosuvastatin, which supports the 
hypothesis of a change in the volume of 
distribution of the drug.  Parallel to this, there was 
a decrease in hypertrophy of myocardiocytes and 
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a normalization of the morphological picture of 
the endothelium of small vessels of the kidneys.   
Use of monotherapy with donor NO L-
arginine (70 and 200 mg / kg), non-selective 
inhibitor of arginase BEC (5 and 10 mg / kg), 
selective inhibitor of arginase 2 Arginazine (1 and 
3 mg / kg) and recombinant darbepoetin (50  and 
500 μg / kg) in the modeling of endothelial 
dysfunction of the pathology revealed their high 
activity, expressed in preventing the increase in 
QED, adrenoreactivity, preservation of 
myocardial reserve and normalization of 
biochemical markers values (Total NO, eNOS 
expression, C-reactive protein, IL-6, TNF  ).  In 
this case, the drugs had a dose-dependent effect 
and were approximately equally effective.   
Use of combined use of L-arginine (200 mg / 
kg) with inhibitors of HMG-CoA reductase by 
simvastatin (8.5 mg / kg), atorvastatin (4.3 mg / 
kg), rosuvastatin (8.5 mg / kg) and 
nanoparticulated rosuvastatin (11.6 mg / kg) 
against the background of endotoxin-induced 
pathology modeling proved to be so effective that 
the values of QED, adrenoreactivity, conservation 
of myocardial reserve and biochemical markers 
(Total NO, eNOS expression, C-reactive protein, 
IL  -6, TNF) did not differ from the indices of 
intact animals.  The combined use of L-arginine 
and statins in the modeling of L-NAME-induced 
pathology also revealed a pronounced additive 
endothelial and cardioprotective effect, 
manifested in a decrease in QED, prevention of a 
decrease in NOx concentration, and an 
improvement in myocardial contractility in 
performing adrenoreactivity and load tests  
resistance.  reduction of hypertrophy of 
myocardiocytes and normalization of the 
morphological picture of the endothelium of 
small vessels of the kidneys.  
Combined use of non-selective inhibitor of 
arginase BEC (10 mg/kg) with simvastatin (8.5 
mg/kg), atorvastatin (4.3 mg/kg), rosuvastatin 
(8.5 mg/kg) and nanoparticulated rosuvastatin 
(11, 6 mg/kg) did not show a positive 
pharmacodynamic interaction both in the 
modeling of endotoxin-induced and L-NAME-
induced pathologies. 
Combined use of the selective inhibitor 
Arginase 2 Argazine (3 mg/kg) with simvastatin 
(8.5 mg / kg), atorvastatin (4.3 mg / kg), 
rosuvastatin (8.5 mg/kg) and nanoparticulated 
rosuvastatin (11, 6 mg/kg) showed ectothelial and 
cardioprotective effect, which is expressed in 
preventing the increase in QED, adrenoreactivity, 
preservation of myocardial reserve and 
normalization of biochemical markers values 
(Total NO, eNOS expression, C-reactive protein, 
IL-6, TNF).  At the same time, combined therapy 
revealed the additive effect of drugs.  A similar 
dynamics was observed with L-NAME-induced 
pathology. 
Use of concomitant use of recombinant 
darbepoetin (500 mcg / kg) with simvastatin (8.5 
mg / kg), atorvastatin (4.3 mg / kg), rosuvastatin 
(8.5 mg / kg) and nanoparticulated rosuvastatin 
(11.6  mg / kg) on the background of modeling 
endotoxin-induced pathology exhibits ectothelial 
and cardioprotective effects.  At the same time, 
combined therapy revealed the additive effect of 
drugs.  Similar dynamics was observed in 
L-NAME-induced pathology, which was 
reflected in a decrease in the endothelial 
dysfunction coefficient, prevention of NOx 
concentration decrease, and improvement of 
myocardial contractility in performing functional 
tests and reducing myocardiocyte hypertrophy.  
Vector analysis of the additive effects of the 
combined use of simvastatin, atorvastatin and 
rosuvastatin inhibitors and nanoparticulated 
rosuvastatin with L-arginine, arginase inhibitors-
BEC and Arginazine and darbepoietin showed 
that, with endotoxin-induced pathology, the 
highest probabilistic percent of additions turned 
out to be  in combinations of rosuvastatin with 
"Arginazine" (3 mg / kg) and dabropoietin 
(500 μg / kg), respectively, 31.9 ± 2.8 and 30.2 ± 
2.9%. 
Thus, the foregoing indicates that the problem 
of pharmacological correction of endotoxin-
induced pathology and its components of 
endothelial dysfunction and multiple organ failure 
does not have a pathogenetically grounded 
pharmacological correction strategy.  One of the 
possible ways is the use of drugs in the mechanism 
of action of which the principles of pharmacological 
pre- and post-conditioning, restriction of the 
activation cascades of LPO, NF-kB and the release 
of pro-inflammatory cytokines, as well as an 
increase in the level of ADMA and TNF-induced 
increase in ICAM are laid.  It seems that for the role 
of "drugs of choice" in this situation the most 
meaningfully claim statins, including 
nanaparticulated dosage forms.  At the same time, 
the potential of L-arginine endothelioprotective 
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agents, nonselective and selective inhibitors of 
arginase 2 and darbopoetin is not fully disclosed. In 
this case, the approaches to experimental research in 
this direction should be formed taking into account 
the possibilities of a complex comparative 
evaluation of the dose-dependent anti-inflammatory 
effects of HMG-CoA reductase inhibitors, their 
cardioprotective effects in coronary-occlusive 
infarction, endothelioprotective effects in 
endotoxin-induced endothelial dysfunction in both 
monotherapy and  in combination with drugs 
possessing endothelioprotective effects of various 
mechanisms of action.  As a control of 
endothelioprotective activity, a well-developed 
model of L-NAME-induced deficiency of nitric 
oxide can be used in our laboratory.  At the same 
time, taking into account the special role of the 
processes of "low gradation inflammation" in the 
development of endotoxin-induced endothelial 
dysfunction, it is necessary to control the level of 
inflammatory markers and the dynamics of 
morphological changes in the "target organs" of the 
myocardium and microvessels of the kidneys.  
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